Indevus Pharmaceuticals (NasdaqNM:IDEV)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Indevus Pharmaceuticals (NasdaqNM:IDEV)

An SI Board Since September 2003

Posts	SubjectMarks	Bans	Symbol
78	14	0	IDEV

Emcee: SemiBull	Type: Unmoderated

Introduction Market Data Compact

This bio-tech equity has grabbed my attention over the summer....most notably because of their Trospium drug. With approval of their closest competitor's (Eli Lilly) drug in the overactive bladder (OAB) being delayed earlier this month (requesting more date on metabolism and drug-to-drug interaction), it might seem that things might be getting brighter for IDEV. It appears that Trospium also avoids the shortcomings of Lilly's drug. Trospium has already been approved in Europe, and an NDA has already been filed and wiaccepted for a 12-month review.

Wachovia cut Indevus to "market perform" from "outperform" on September 12, 2003.

Do I see an opportunity? Is anyone else following this stock?

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
78	Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals Monday January 5, 2009,	Steve Lokness	-	1/5/2009
77	went up from $1.20 to $1.80. Following it over 2 years on sidelines. Too bad!	mlkr	-	7/3/2008
76	<i>I am going to quickly forget what you've told me about this appeal	Biomaven	-	6/6/2008
75	I can honestly say that I have never looked at that section of the FDA regulatio	kenhott	-	6/6/2008
74	If the FDA doesn't accede to a request for an AC they have to state their re	Biomaven	-	6/6/2008
73	Does the FDA have to give an AC on such an appeal?	kenhott	-	6/6/2008
72	Well they presumably have the right of appeal to an Advisory Committee. At that	Biomaven	-	6/6/2008
71	I don't know Peter. Meaning I don't know. But I would think that a suc	kenhott	-	6/6/2008
70	<i>You say you want to market this in a <b>blue</b> container?	Biomaven	-	6/5/2008
69	The FDA is sending a pretty clear and now pretty consistent message about how th	kenhott	-	6/5/2008
68	Indevus Pharma Slides on FDA Delay Adam Feuerstein 06/04/08 - 09:55 AM EDT Ef	Doc Bones	-	6/5/2008
67	Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status Wednesday June	Doc Bones	-	6/4/2008
66	From AGN's Q report today.....appears they think it will be a good launch th	Arthur Radley	-	1/30/2008
65	Taken from Yahoo.... Sanctura Scripts --- Did anyone post here the scripts	Arthur Radley	-	1/23/2008
64	From January 22, 2008 UBS report: N o PDUFA Delays for New Nebido Dosing ?? Res	Arthur Radley	-	1/23/2008
63	Oppenheimer and Leerink Swann issue reports on IDEV today.. Oppenheimer is a in	Arthur Radley	-	1/14/2008
62	Just one reason I'm buying IDEV at these levels........approved drug list gr	Arthur Radley	-	12/5/2007
61	We have a classic case of a shoot out at the OK Corral....we have the $7.50 gang	Arthur Radley	-	11/28/2007
60	I will pound the table one more time for IDEV...in the biotech arena this seems	Arthur Radley	-	11/28/2007
59	Finally starting buying IDEV today at the $7.10 level......with approved drugs a	Arthur Radley	-	11/20/2007
58	If one follows the technicals and option trend.....IDEV is a screaming BUY. Huge	Arthur Radley	-	11/13/2007
57	Go figure....IDEV gets the best solution to the marketing issue for their drug a	Arthur Radley	-	9/19/2007
56	Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Th	idos	-	8/17/2007
55	thestreet.com Feursteins comments on IDEV today! I agree with him...	Arthur Radley	-	8/11/2007
54	CIBC- Sanctura XR Gift-Wrapped With Best-in-Class Profile; Can Esprit Now Delive	idos	-	8/6/2007

Go to reply# or date (mm/dd/yy):